VP3.15
Based on 3 publication(s) in Google Scholar
VP3.15 is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC50s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS).
For research use only. We do not sell to patients.
- CAS No.: 1281681-54-6
- Formula: C20H22N4OS
- Molecular Weight:366.48
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) VP3.15
More
Biological Activity
IC50: 1.59 μM (PDE7), 0.88 μM (GSK-3)[1]
Chemical Information
-
CAS No. 1281681-54-6
-
Molecular Weight 366.48
-
Formula C20H22N4OS
-
SMILES
N1(CC/N=C2N=C(C3=CC=CC=C3)N(C4=CC=CC=C4)S/2)CCOCC1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
J Biol Chem
REDD1-dependent GSK3β signaling in podocytes promotes canonical NF-κB activation in diabetic nephropathy. [Abstract]2025 Jan 27:108244. PMID: 39880090 -
J Biol Chem
REDD1-dependent GSK3β dephosphorylation promotes NF-κB activation and macrophage infiltration in the retina of diabetic mice. [Abstract]2023 Aug;299(8):104991. PMID: 37392853 -
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
VP3.15 Related Classifications
HY-128879 Related Classifications
Powered by Bioz